HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reckitt's Q1 VMS Results Exceed Expectations Driven By Sales In China

Executive Summary

Reckitt’s VMS product sales exceeded expected 4% to 5% Q1 growth due to strong sales in China. Company also increased 2022 guidance due to a strong start. 

You may also be interested in...

Reckitt To Exit Russia In Response To War

Reckitt Benckiser has committed to transferring ownership of its operations in Russia following the country's invasion of Ukraine in February.

Euro Q1 Consumer Health Earnings Preview: Sanofi, Reckitt, GSK And Bayer

Major Europe-based consumer health players Sanofi, Reckitt, GSK and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2022 results over the coming weeks.

Reckitt Divests Dermicool To India's Emami

Reckitt will divest heat rash treatment Dermicool to India's Emami as it continues to reshape its portfolio around brands with higher growth potential.

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts